Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822398 | 0.85 | MAPT (0.61) | THRBMAPTTP53KDM4ESMN1; SMN2 | |
| SCHEMBL822518 | 0.85 | MAPT (0.67) | THRBMAPTTP53KDM4ESMN1; SMN2 | |
| SCHEMBL1719394 | 0.85 | MAPT (0.78) | THRBMAPTTP53KDM4ESMN1; SMN2 | |
| SCHEMBL17297256 | 0.79 | THRB (0.69) | THRBMAPTTP53KDM4ESMN1; SMN2 | |
| SCHEMBL1719088 | 0.77 | MAPT (0.74) | THRBMAPTTP53KDM4ESMN1; SMN2 | |
| SCHEMBL1718510 | 0.77 | THRB (0.85) | THRBMAPTTP53KDM4ESMN1; SMN2 | |
| SCHEMBL1718816 | 0.77 | THRB (0.86) | THRBMAPTTP53KDM4ESMN1; SMN2 | |
| SCHEMBL1718639 | 0.77 | MAPT (0.84) | THRBMAPTTP53KDM4ESMN1; SMN2 | |
| SCHEMBL1718821 | 0.77 | MAPT (0.84) | THRBMAPTTP53KDM4ESMN1; SMN2 | |
| SCHEMBL1718384 | 0.77 | THRB (0.71) | THRBMAPTTP53KDM4ERXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198891-B2 | Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase | NEW YORK UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20110288083-A1 | METHOD OF TREATING CANCER BY INHIBITION OF PROTEIN KINASE-LIKE ENDOPLASMIC RETICULUM PROTEIN KINASE | NEW YORK UNIVERSITY (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288083-A1 | METHOD OF TREATING CANCER BY INHIBITION OF PROTEIN KINASE-LIKE ENDOPLASMIC RETICULUM PROTEIN KINASE | ERN1, ERN2, EEF2K | THRB 1381/4885MAPT 2510/4885TP53 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.